ABIVAX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.38 EUR | -0.59% |
|
-4.84% | +36.25% |
Presentation Operator MessageOperator (Operator)Good morning. And welcome to the ABIVAX KOL we...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Abivax develops innovative treatments modulating the body's natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn's disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). The Company's mission is to utilize its drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.38
EUR
Average target price
37.59
EUR
Spread / Average Target
+180.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.25% | 907M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- Transcript : ABIVAX Société Anonyme - Special Call
